The SARS-CoV-2 (COVID-19) pandemic has already claimed over 200,000 lives. Quite early on in this pandemic, it was recognised that the virus triggers the immune system leading to a cytokine storm in some severely ill patients [1]. This hyper-responsiveness has been suggested to be the predominant aetiology for clinical deterioration and mortality in patients with this infection [2]. More recently, there have been several reports of increased thrombotic events in these patients [3–6]. From a laboratory perspective, this hypercoagulability is reflected in the marked elevation of the fibrinolytic marker, D-dimer, in almost all hospitalised COVID-19 patients [7]. We must, therefore, ask ourselves what is the link between the extremes of the immune system, presenting as cytokine storm, and the extremes of coagulation, presenting as arterial and venous thromboembolism?

**Immunothrombosis and differences in COVID-19 clinical presentation**

In embryological organisms such as the horseshoe crab, the haemostatic system and the immune system were one and the same (haemolymph) [8]. The haemostatic system, by forming a blood clot, not only prevented the loss of important nutrients but also formed a barrier to pathogen invasion. This immune function has been explored by several researchers as an immunothrombosis concept [9]. The various components of the haemostatic system, including the platelets, coagulation factors and thrombin, are all immune workers. They function as chemotactic to the immune cells, as well as being activated by the immune system themselves [10–12]. This bidirectional relationship could explain some common observations with COVID-19.

In the pandemic so far, we have seen that children rarely get a severe illness despite having proven infection, although there have been recent reports of a hyperinflammatory response in very small numbers of children [13]. This rarity of severe disease may be explained by the rarity of thrombotic complications in the paediatric age group in the absence of underlying cancer or a central venous access device [14]. Similarly pregnant women, despite being at risk of clotting problems, tend to have milder illness. This may be because their immune system is suppressed during the gestational period to avoid fetal rejection and hence the double hit of immunothrombosis does not come into play [15]. On the other hand, older individuals, who are more prone to getting thrombotic complications in the pre-COVID-19 era, are more likely to get severe disease. The differences in mortality between the South East Asian and Western cohorts affected by COVID-19 could also be explained by the lack of prothrombotic tendencies in the South East Asian population [16]. We must wonder, however, why do some Western patients affected by the virus get severe respiratory compromise requiring critical care support, whereas others have a relatively mild illness.

**Localised pulmonary to systemic coagulopathy**

The SARS-CoV-2 gains entry predominantly through the lungs. In the lungs, a localised coagulation system or
broncho-alveolar haemostasis is present which tries to fight the infection along with the immune cells [17]. The proof for this lung-specific clot formation comes from two things. Firstly, the marked acute phase response includes platelets and fibrinogen in addition to other well-known markers such as C-reactive protein and ferritin. Platelet counts are increased in these patients in the initial stages (uncommonly reported in patients with infectious diseases) and are almost never severely low, even in critically ill COVID-19 patients [18]. Similarly, fibrinogen is markedly raised in these patients and has been historically recognised as a marker of hypercoagulability [19]. Secondly, postmortem examinations have found evidence of pulmonary microthrombi in patients with COVID-19 [20]. There are also suggestions that the different ventilatory patterns in COVID-19 may suggest microthrombi to be a key component of clinical deterioration [21]. In non-severe COVID-19, these microthrombi are broken down by the highly active fibrinolytic function in the lungs to allow gas exchange which is noted as an elevation in D-dimers. In severely ill patients, the pulmonary coagulation system becomes markedly activated. This would be clinically manifest as increased oxygen requirements and possibly as an increased incidence of renal impairment (latest ICNARC data shows 23% of patients require renal support, https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports, accessed 03/05/2020) and, in the worst cases, arterial and venous thrombosis including limb, intestinal and cerebral ischaemia and multi-organ failure. What is the clinical relevance of this spectrum of localised pulmonary coagulopathy to the more widespread systemic coagulopathy?

**Antithrombotic management**

Based on several reports of hypercoagulability, it is now recognised that all patients with COVID-19 requiring hospitalisation require prophylactic anticoagulation in the absence of absolute contra-indications [22, 23]. However, in patients where localised pulmonary coagulopathy may progress or have already become systemic, prophylactic anticoagulation might be inadequate. There are currently several trials looking at increased doses of anticoagulation, even therapeutic anticoagulation in such patients. It is important to bear in mind that systemic coagulopathy may not be treated with full-dose anticoagulation in all cases. It is likely that extra-pulmonary coagulopathy requires more aggressive antithrombotic therapies (e.g. additional antiplatelet drugs or thrombolysis) and treatments which can impact on the immunothrombosis models (e.g. immunomodulatory agents and anticomplement drugs) [24–27]. It would be ideal in these situations to depend on laboratory markers which can predict the transition from the beneficial pulmonary coagulation activation to harmful systemic spread.

Based on currently available laboratory markers, of which D-dimers seem to be the most consistent, we provide a suggested approach but stress that this requires confirmation from ongoing trials (Fig. 1). When the patient presents to the hospital, if the D-dimers are increased, prophylactic anticoagulation with low molecular weight heparin should be given to all patients in the absence of contra-indications as per current guidance documents [22, 23]. If D-dimers continue to increase despite prophylactic anticoagulation and the patient deteriorates clinically, consideration should be made to intensifying anticoagulation; trials are examining double dose of prophylaxis or treatment dose anticoagulation. In these patients, it is important to consider imaging looking for pulmonary thrombi or thrombi in the systemic circulation, if clinical signs are suggestive. If thrombi are identified, therapeutic dose anticoagulation should be administered. It should, however, be borne in mind that patients with systemic anticoagulation may not respond to anticoagulation and additional strategies like antiplatelets and others (described above) should be considered in a trial setting. Thrombolysis using inhaled or systemic tissue plasminogen activator has been attempted in some patients who worsen despite therapeutic anticoagulation and maximal critical care support [28]. Regarding anticoagulation, the drug of choice is low molecular weight heparin due to better bioavailability and ease of use. However, in patients who may have severe renal impairment or extremely high risk of bleeding, unfractionated heparin may be considered.

**Role of viscoelastic testing**

Some early reports suggest that point of care viscoelastic tests such as thrombo-elastography (TEG) or rotational thrombo-elastometry (ROTEM) may be helpful in guiding treatment. Data from observational studies has shown evidence of hypercoagulability on TEG with decreased ‘r’ and ‘k’ times and increased maximum amplitudes (MA) in patients with known raised fibrinogen and d-dimer levels [29] This was also demonstrated with the ROTEM with a shorter clot formation time and high clot firmness [30]. A separate study using the Quantra (Hemosonics, Charlottesville, VA, USA) again demonstrated a procoagulant profile with increased clot strength, increased platelet and fibrinogen contributions in patients with known elevated d-dimer and fibrinogen levels [24]. It may be that
those with greater hypercoagulability have a worse outcome. In addition, there may be a possibility of using one of these point of care viscoelastic tests as a screening tool although this requires a great deal of further research. It may also be that these tests can be used to optimise anticoagulation therapy, particularly in the acute intensive care unit (ICU) setting, although this again needs further research.

**Bleeding**

Overt bleeding is rare in COVID-19 patients although there are patients who develop disseminated intravascular coagulation (DIC) in common with many patients who are critically unwell. However, heparinisation may be difficult to manage. Helms et al. recently reported that 96.6% of patients requiring renal replacement therapy experienced circuit clotting, and in 12 patients requiring extracorporeal membrane oxygenation (ECMO), there were 3 thrombotic occlusions of the centrifugal pump (in 2 patients) requiring prompt pump replacement [31]. This in turn may lead the clinician to increase heparin therapy leading to iatrogenic bleeding. The same authors found that 50 out of 57 patients tested had positive lupus anticoagulant. Lupus anticoagulant is known to prolong the activated partial thromboplastin time (APTT); using the APTT to guide heparin therapy may result in underdosing, leading to an increase in thrombosis in artificial circuits.

**The future**

Currently, the only marker for coagulation activation is markedly elevated D-dimers, which are not specific to systemic coagulopathy. Since the vascular endothelium is at the interface of coagulation and immune system (recently termed as endothelilitis), markers of endothelial activation would be an interesting research area [32, 33]. Ruan et al. showed that interleukin-6 concentrations differed significantly in survivors and non-survivors of COVID-19, with non-survivors having almost double the level as survivors [34]. Ranucci et al., discussing 16 patients with COVID-19 who required mechanical ventilation, found an increase in interleukin-6 (IL-6) levels, which correlated with increased fibrinogen levels, confirming the link between inflammation and a procoagulant state [24].

It is vital that healthcare workers who deal with patients suffering from COVID-19 are familiar with the spectrum of coagulopathy in this disease. However, there remain many questions which need to be answered. These include should all patients hospitalised with severe COVID-19 be

---

**Figure 1** Antithrombotic management of COVID-19 coagulopathy based on D-dimers and platelet counts.
treated empirically with therapeutic anticoagulation until venous thromboembolism is discounted? How should we manage anticoagulation for these patients in the ICU for renal replacement therapy or ECMO? And as we restart semi-elective surgery should we give patients subsequently found to be COVID-19 positive additional thromboprophylaxis? If so, for how long, when do we think the additional risk has passed? At present we simply do not have adequate answers to these questions.

Acknowledgements

JT has received honoraria from Bayer, BMS-Pfizer, Daichii-Sankyo, Boehringer, Mitsubushi, Novo Nordisk, Octapharma, Amgen, Norgine, Alexion, Sobi, CSL-Behring and Roche-Chugai, none of which were involved in this editorial. SA is an editor of Anaesthesia. She has received research funding and honoraria from Haemonetics, Pharmacosmos, Octapharma, CSL Behring and Nordic Pharma, none of which were involved in this editorial. No other competing interests declared.

References
1. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. Journal of Infection 2020; 80: 607–13.
2. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clinical Immunology 2020; 214: 108393.
3. Liljos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. Journal of Thrombosis and Haemostasis 2020; 18: 1743–46.
4. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis 2020; 18: 1094–9.
5. Klok FA, Kruip MJHA, van der Meer CJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research 2020; 191: 145–47.
6. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 2020; 18: 1421–24.
7. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 2020; 18: 844–7.
8. Iwanaga S, Kawabata S, Muta T. New types of clotting factors and defence molecules found in horseshoe crab hemolymph: their structures and functions. Journal of Biochemistry 1998; 123: 1–15.
9. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nature Reviews Immunology 2013; 13: 34–45.
10. Conway EM. Reincarnation of ancient links between coagulation and complement. Journal of Thrombosis and Haemostasis 2015; 13(Suppl 1): S121–S132.
11. Maas C, Renné T. Coagulation factor XII in thrombosis and inflammation. Blood 2018; 131: 1903–9.
12. Herter JM, Rossaint J, Zarbock A. Platelets in inflammation and immunity. Journal of Thrombosis and Haemostasis 2014; 12: 1764–75.
13. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395: 1607–8.
14. Chan AK, Monagle P. Updates in thrombosis in pediatrics: where are we after 20 years? Hematology 2012; 2012: 439–43.
15. Della Gatta AN, Rizzo R, Pilu G, Simonazzi G. COVID19 during pregnancy: a systematic review of reported cases. American Journal of Obstetrics and Gynecology 2020; 223: 36–41.
16. Fogarty H, Townsend L, Cheallaigh CN, et al. COVID-19 coagulopathy in caucasian patients. British Journal of Haematology 2020; 189: 1044–49.
17. Glas GJ, Van Der Sluijs KF, Schultz MJ, Hofstra JJ, Van Der Poll T, Levi M. Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome. Journal of Thrombosis and Haemostasis 2013; 11: 17–25.
18. Yang X, Yang Q, Yang W, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. Journal of Thrombosis and Haemostasis 2020; 18: 1469–72.
19. Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood 2011; 117: 4953–63.
20. Dohlknoff M, Duarte-Neto AN, de Almeida Monteiro RA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. Journal of Thrombosis and Haemostasis 2020; 18: 1517–19.
21. Gattinoni L, Chiumento D, Caironi P, et al. COVID pneumonia: different respiratory treatments for different phenotypes? Intensive Care Medicine 2020; 14: 1–4.
22. Thachil J, Wada H, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis 2020; 18: 1023–6.
23. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. Journal of the American College of Cardiology 2020; 16: 2950–73.
24. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern if patients with COVID-19 acute respiratory distress syndrome. Journal of Thrombosis and Hemostasis 2020; 18: 1747–51.
25. Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. Journal of Thrombosis and Haemostasis 2020; 18: 1548–55.
26. Lucciardi F, Giani T, Baldini L, Favalli EG, Caporali R, Cimaz R. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. Pediatric Rheumatology Online Journal 2020; 18: 35.
27. Karasu E, Nilsson B, Köhl J, Lambris JD, Huber-Lang M. Targeting complement pathways in polytrauma- and sepsis-induced multiple-organ dysfunction. Frontiers in Immunology 2019; 10: 543.
28. Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. Journal of Thrombosis and Haemostasis 2020; 18: 1752–55.
29. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. Journal of Thrombosis and Haemostasis 2020; 18: 1738–42.
30. Spiezia L, Boscolo A, Poletto F, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. *Thrombosis and Haemostasis* 2020; **120**: 998–1000.

31. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicentre prospective cohort study. *Intensive Care Medicine* 2020; **46**: 1089–98.

32. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 2020; **395**: 1417–8.

33. Page AV, Liles WC. Biomarkers of endothelial activation/dysfunction in infectious diseases. *Virulence* 2013; **4**: 507–16.

34. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on analysis of data of 150 patients from Wuhan, China. *Intensive Care Medicine* 2020; **46**: 846–48.